Viatris Nixes Biogen's Extra 1-Year Protection Over MS Drug
A court agreed on Wednesday to cancel a European Commission decision that extended Biogen's market protection for the multiple sclerosis drug tecfidera for an extra year, allowing Viatris to enter the...To view the full article, register now.
Already a subscriber? Click here to view full article